Alerta

CLOSED-LOOP ARTIFICIAL PANCREAS INSULIN INFUSION CONTROL SYSTEM

Resumen de: US2025235606A1

The invention discloses a closed-loop artificial pancreas insulin infusion control system, including: a detection module and an infusion module, a detection control unit is set in the detection module, an infusion control unit is set in the infusion module, and at least one calculation control unit is set in the detection module and the infusion module for calculating insulin infusion information and/or further processing of different insulin infusion information. Therefore, the closed-loop artificial pancreas insulin infusion control system can automatically switch the control unit according to different situations to avoid affecting the user experience due to the failure of a module or even bringing safety risks to the user, and to avoid replacing the whole device when only part of the function of some components fails, and to improve the utilization rate of each component of the closed-loop artificial pancreas.

CLOSED-LOOP ARTIFICIAL PANCREAS INSULIN INFUSION CONTROL SYSTEM

Resumen de: US2025235609A1

A closed-loop artificial pancreas insulin infusion control system is provided. The system includes a detection module configured to detect the current blood glucose level G continuously, a program module configured to preset with an rPID algorithm that converts the asymmetric blood glucose in the original physical space to the approximately symmetric blood glucose risk in the risk space and target blood glucose level, and an infusion module which is connected to and controlled by the program module and is configured to infuse insulin according to the corresponding output instructions calculated by the rPID algorithm. The simple and robust characteristics of PID algorithm can be retained, and giving the rPID algorithm the advantages of precision and flexibility, realizing precise control for closed-loop artificial pancreas insulin infusion system.

LASER BLOOD COLLECTION AND BLOOD GLUCOSE MEASUREMENT DEVICE

Resumen de: WO2025155053A1

The present invention relates to a laser blood collection and blood glucose measurement device. The laser blood collection and blood glucose measurement device comprises: an examinee identification unit for outputting identification information about examinees; a storage unit for storing examinee information corresponding to each piece of identification information and the laser intensity levels corresponding to the respective examinees; an operation control unit connected to the examinee identification unit and the storage unit; a capacitor module unit connected to the operation control unit and including a capacitor; and a laser output module unit that is connected to the capacitor module unit and outputs a laser of a corresponding intensity to the skin of the current examinee according to the charging voltage applied from the capacitor module unit, thereby causing bleeding. The operation control unit is connected to the examinee identification unit, identifies the examinee corresponding to the identification information applied from the examinee identification unit among the examinees stored in the storage unit and stores the examinee as the current examinee in the storage unit, determines the laser intensity level corresponding to the current examinee among the laser intensity levels stored in the storage unit, and controls the charging voltage of the capacitor according to the determined laser intensity level.

Systems and methods for distributing continuous glucose data

Resumen de: AU2025205069A1

MARKED-UP COPY The present disclosure relates to systems, devices and methods for receiving biosensor data acquired by a medical device, e.g., relating to glucose concentration values, and controlling the access and distribution of that data. In some embodiments, systems and methods are disclosed for monitoring glucose levels, displaying data relating to glucose values and metabolic health information, and controlling distribution of glucose data between applications executing on a computer, such as a smart phone. In some embodiments, systems and methods are disclosed for controlling access to medical data such as continuously monitored glucose levels, synchronizing health data relating to glucose levels between multiple applications executing on a computer, and/or encrypting data. The present disclosure relates to systems, devices and methods for receiving biosensor data acquired by a medical device, e.g., relating to glucose concentration values, and controlling the access and distribution of that data. In some embodiments, systems and methods are disclosed for monitoring glucose levels, displaying data relating to glucose values and metabolic health information, and controlling distribution of glucose data between applications executing on a computer, such as a smart phone. In some embodiments, systems and methods are disclosed for controlling access to medical data such as continuously monitored glucose levels, synchronizing health data relating to glucose levels between

ANALYTE AND ENVIRONMENT SENSORS

Resumen de: US2025235131A1

Disclosed are devices, systems and methods for in vivo monitoring of localized environment conditions within a patient user by measuring analytes, including glucose, oxygen, and/or other analytes. In some aspects, a sensor device includes a wafer-based substrate, at least one electrochemical sensor two-electrode contingent including a working electrode and a reference electrode on the substrate and configured to detect a target analyte in a body fluid when the sensor device is deployed within a subject's body, where the working electrode is functionalized by a chemical layer configured to facilitate a reaction involving the target analyte that produces an electrical signal; and an electronics unit in communication with the electrochemical sensor electrode contingent to transmit the electrical signal to an external processor.

INSULIN DOSAGE DETERMINATION SYSTEM BASED ON PERSONALIZED ARTIFICIAL INTELLIGENCE

Resumen de: US2025239350A1

Provided is a personalized artificial intelligence-based insulin dose determination system includes an interface layer capable of communicating with the insulin pump and the continuous blood glucose system, and signal-processing information from the insulin pump and the continuous blood glucose system, a control layer receiving the signal-processed information from the interface layer and generating output information associated with an insulin infusion amount, an outer safety layer determining whether or not the output information generated from the control layer satisfies a preset threshold condition, and delivering the output information to the interface layer when the output information satisfies the preset threshold condition, and a personalized safety layer receiving prescription information including Total Daily Dose of Insulin (TDD) information of the user from the outside to determine a personalized safety control variable, and transmitting the determined control variable as an input variable of the control layer.

SELF-INSERTING TROCARLESS ANALYTE-SENSING CANNULA

Resumen de: AU2024209583A1

The disclosure describes devices and methods for insertion and delivery of insulin or an insulin analog formulation and measurement of subcutaneous glucose concentration. A device for delivery of insulin or an insulin analog formulation and measurement of subcutaneous glucose concentration, may comprise: (a) a tube comprising a proximal end and a distal end, wherein the proximal end is in fluid communication with a source of the insulin or insulin analog formulation, and wherein the distal end is configured to deliver the insulin or insulin analog formulation subcutaneously; (b) a glucose sensor disposed along a central axis of the tube; and (c) a penetrating body disposed along the central axis of the tube, wherein the penetrating body comprises a cross-sectional area no more than a cross-sectional area of the glucose sensor.

NEUROMODULATION SYSTEM TO INDUCE CHANGES IN GLYCEMIC REGULATORY SYSTEM PLASTICITY

Resumen de: AU2023420510A1

Current Type 2 Diabetes Mellitus treatments include life-style management, pharmaceuticals and may include bariatric surgery for the morbidly obese. However, issues with compliance, side effects and permanent anatomical alterations provide a need for an alternative therapy to modulate a peripheral nerve, such as the vagus nerve, in a manner that causes a plastic change in the glycemic regulatory system, with or without the involvement of the central nervous system (CNS), that changes the activity of an organ and thereby changing the activity of that organ. Low energy vagus nerve neuromodulation has potential as a new treatment for type 2 diabetes mellitus by inducing plasticity of the body's glycemic regulatory system with low energy transient stimulation. This will allow for effective use of a small implantable pulse generator that requires infrequent, or no, charging during the life of the device.

UNIFIED PLATFORM FOR MONITORING AND CONTROL OF BLOOD GLUCOSE LEVELS IN DIABETIC PATIENTS

Resumen de: US2025235155A1

A flexible system for utilizing data from different monitoring techniques and capable of providing assistance to patients with diabetes at several scalable levels, ranging from advice about long-term trends and prognosis to real-time automated closed-loop control (artificial pancreas). These scalable monitoring and treatment strategies are delivered by a unified system called the Diabetes Assistant (DiAs) platform. The system provides a foundation for implementation of various monitoring, advisory, and automated diabetes treatment algorithms or methods. The DiAs recommendations are tailored to the specifics of an individual patient, and to the patient risk assessment at any given moment.

SIGNAL QUALITY ASSESSEMENT SYSTEM AND BLOOD GLUCOSE LEVEL PREDICTION SYSTEM BASED ON PHOTOPLETHYSMOGRAPHY

Resumen de: US2025235127A1

The present invention relates to a signal quality assessment system and a blood glucose level prediction system based on photoplethysmography. The signal quality assessment system comprises a near-infrared light photoplethysmography sensor, a Bluetooth module, an AI acceleration platform, and an electronic device. The AI acceleration platform serves as the central analysis unit, receiving PPG signals from the front-end sensing unit via an interface. Signal processing, including bandpass filtering composed of high-pass and low-pass filters and data normalization, is executed by the processor. Configurable AI chips are used to evaluate the quality of PPG signals, facilitating the discard of unwanted signals and subsequent reconstruction for blood glucose assessment. Processed PPG signals and the corresponding assessed blood glucose values are transmitted to a display. The display provides a comprehensive and real-time view of the monitored data, enabling efficient and timely interpretation of blood glucose values.

GLUCOSE SENSOR FOR GLYCEMIC ASSESSMENT

Resumen de: US2025235100A1

An analyte assessment system includes an analyte sensor, a remote device, and a software application. The remote device is configured to retrieve sensor data of a patient from the analyte sensor. The software application is configured to receive an order for analyte assessment associated with an electronic medical record (EMR) of the patient, generate or retrieve a unique identifier associated with the order, authenticate the unique identifier with the remote device, activate the analyte sensor based on the unique identifier, retrieve sensor data from the remote device, generate a report, and upload the report to the EMR of the patient. Advantageously the system can streamline requests and delivery of analyte reports for third parties, reduce in-person patient interactions and time delays, reduce third party effort, increase security and integrity of patient data, update an EMR of the patient, and operate in a blinded mode for unbiased patient analyte assessment.

MANAGEMENT DEVICE AND METHOD FOR DISPLAYING GLUCOSE INFORMATION

Resumen de: WO2024055249A1

A management device for displaying glucose information. The screen of the management device is divided into the plurality of display areas, at least comprising a first display area for displaying the status of the management device, a second display area for displaying real-time glucose information, and a third display area for displaying historical glucose concentration information. The user can intuitively and easily get the glucose information in the body.

DRUG INFUSION SYSTEM WITH GRAPHICAL USER INTERFACE

Resumen de: EP4588494A1

The invention discloses a drug delivery system with graphical user interface comprises detection device, for detecting the blood glucose level of the user; an infusion device, for infusing a drug into the user's body; and a control device, wirelessly communicated with the detection device and the infusion device, the control device controlling the drug delivery of the infusion device, and the control device provided with a graphical user interface, the graphical user interface comprising a main screen, the main screen comprising an insulin information display area and a blood glucose information display area, wherein the insulin information display area comprising insulin infusion status information, the graphical user interface displays the insulin infusion status information in a graphical and/or textual manner, to facilitate the user to intuitively know the insulin infusion status information and blood glucose information at that time.

ADJUSTING INSULIN DELIVERY RATES

Resumen de: EP4588437A2

The present disclosure relates to a diabetes management system and a method for the same. The system includes a pump device and a controller, where the controller is in electrical communication with a drive system for controlling dispensation of insulin from an insulin cartridge. The controller, over a first diurnal time period, communicates electrical control signals to the drive system to cause insulin to be dispensed based on a baseline basal insulin rate that is stored. The controller also receives at least blood glucose data to control dispensation of insulin in amounts variable from the baseline basal insulin rate. Additionally, the controller modifies the baseline basal insulin rate that is stored for a second diurnal time period that is at least 20 hours after the first diurnal period, based on an amount of insulin actually dispensed during the first diurnal time period.

SYSTEMS AND METHODS FOR DIABETES MANAGEMENT

Resumen de: CN119856162A

Systems, devices, and methods are provided for incorporating a drug delivery device into an integrated management system. The integrated management system may be an integrated diabetes management system and may include a glucose monitor, a connected insulin pen, and software. An integrated management system may generate a plurality of reports, which may include data related to analyte levels (e.g., glucose levels) and delivered drugs (e.g., delivered insulin). The integrated system may also include a mode in which certain types of data are no longer shared and/or stored if the user does not log in the account. The type of data shared and/or stored when the user does not log in the account may be different from the type of data shared and/or stored when the user logs in the account.

CLOSED-LOOP ARTIFICIAL PANCREAS INSULIN INFUSION CONTROL SYSTEM

Resumen de: US2025229023A1

The invention discloses a closed-loop artificial pancreas insulin infusion control system, including: detection module, an infusion module and an electronic module, the detection module, the infusion module and the electronic module all equipped with a control unit, and each control unit is preset with a first algorithm, a second algorithm and a third algorithm correspondingly. When different priority conditions are met, different modules determine the current insulin infusion information. Therefore, the closed-loop artificial pancreas insulin infusion control system can automatically switch control units according to different situations, so as to avoid affecting the user experience and even bringing security risks to users when a module set with the control unit cannot work normally.

DRUG INFUSION DEVICE WITH INTEGRATED POWER SUPPLY AND ARTIFICIAL PANCREAS

Resumen de: US2025229018A1

A drug infusion device with integrated power supply includes a drug reservoir, used for accommodating the drug to be infused, provided with a piston and a screw; a driving wheel, connected with the screw, driving the screw to push the piston forward by rotation; a power supply, used to supply power to the infusion device, including a power supply shell, a power supply cell, electrolyte and a cover plate; and a case, including an upper case and a lower case, for accommodating the drug reservoir, the drive wheel and the power supply. The power supply shell is integrated with the lower and/or the cover plate is integrated with the upper case.

SYSTEMS AND METHODS FOR HIGH FIDELITY FAST SIMULATION OF HUMAN IN THE LOOP HUMAN IN THE PLANT (HIL-HIP) SYSTEMS

Resumen de: US2025232078A1

Examples of a simulation framework are provided to evaluate time varying systems using a piecewise linear time invariant simulation (PLIS) approach. The simulation framework can be configured for an artificial pancreas wireless network system that controls blood glucose in Type 1 Diabetes patients with time varying properties such as physiological changes associated with psychological stress and meal patterns.

WIRELESS HEART TELEMETRY ELECTRODES AND PATIENT MONITORING SYSTEM

Resumen de: WO2025151241A1

The wireless heart telemetry device and accompanied patient monitoring system provides continuous patient monitoring in a comfortable and streamlined design for healthcare settings by providing electrocardiogram (ECG) physiological data in a wireless skin patch device. The wireless heart telemetry device integrates into a full patient monitoring system to provide additional vital physiological patient data in wireless system. This additional physiological data includes pleth, blood oxygen saturation (SPO2), blood pressure, heart rate, respiration rate, temperature, and glucose. The pulse oximeter portion of the system includes mechanical designs such as a finger clip, ring, and bracelet design for enhanced usage, accuracy, and comfort. Another example embodiment of the pulse oximeter portion of the system includes fall detection, bed alarm, and location monitoring services. An additional example embodiment includes a melanin bias reducing pulse oximeter.

NON-INVASIVE MEASUREMENT DEVICE

Resumen de: WO2025150098A1

This non-invasive measurement device comprises: a light source unit 10 that emits excitation light; an irradiation optical system 11 that irradiates skin tissue 2 with the excitation light; a detection optical system 12 that collects Raman-scattered light from the skin tissue 2; a spectroscope 13 that separates the Raman-scattered light; and an analysis device 14 that analyzes a spectroscopic signal obtained as a result of the separation by the spectroscope so as to measure blood sugar level. The irradiation optical system 11 forms the excitation light into minute beam spots in a dot pattern and irradiates the skin tissue 2 obliquely with the excitation light.

NON-INVASIVE MEASUREMENT DEVICE

Resumen de: WO2025150099A1

A non-invasive measurement device according to the present invention comprises: a light source unit 10 which emits excitation light; an irradiation optical system 11 which irradiates skin tissue 2 with the excitation light; a detection optical system 13 which collects Raman scattered light from the skin tissue 2; a spectroscope 14 which disperses the Raman scattered light; and an analysis device 15 which analyzes a spectral signal obtained as a result of the dispersion by the spectroscope 14 and measures a blood glucose level. The irradiation optical system 11 shapes the cross section of the excitation light into a ring and irradiates the skin tissue 2 with the excitation light, and the detection optical system 13 is positioned to detect light returned from a part of the skin tissue 2 that is the central portion of a ring-shaped beam spot irradiated on the skin tissue 2.

CLOUD-BASED PORTABLE SYSTEM FOR NON-INVASIVE REAL-TIME BLOOD GLUCOSE MEASUREMENT

Resumen de: US2025228475A1

One embodiment is a method for implementing a cloud-based portable miniaturized system for performing non-invasive blood glucose level measurement in real time. The method includes using an optical source to emit optical radiations at certain wavelengths through breath in an air collection chamber; receiving the emitted optical transmissions at a photodetector; converting the received optical transmissions to digital data; accumulating the digital data for a first time period; and periodically transmitting the accumulated digital data to a cloud service for further processing.

SYSTEMS AND METHODS OF PREDICTING AND MANAGING BLOOD GLUCOSE LEVELS IN INDIVIDUALS

Resumen de: US2025228501A1

Provided herein are systems and methods of predicting and managing blood glucose levels in individuals, including systems and methods of predicting blood glucose levels based on predicted future glucose factors. Also provided herein are systems and methods of recommending glucose interventions based thereon. It is appreciated by the present disclosure that it is better to prevent extreme blood glucose levels before they occur than merely detecting such levels when they occur. Accordingly, the systems and methods described herein utilized a combination of contextual information and current time glucose measurements/estimates to predict the likelihood of different scenarios that might lead to such extreme levels before they occur.

NEAR-IR GLUCOSE SENSORS

Resumen de: US2025230174A1

Glucose-sensing luminescent dyes, polymers, and sensors are provided. Additionally, systems including the sensors and methods of using these sensors and systems are provided.

SENSOR MODEL SUPERVISOR FOR A CLOSED-LOOP INSULIN INFUSION SYSTEM

Nº publicación: US2025229024A1 17/07/2025

Solicitante:

MEDTRONIC MINIMED INC [US]
MEDTRONIC MINIMED, INC

Resumen de: US2025229024A1

Techniques related to temporary setpoint values are disclosed. The techniques may involve causing operation of a fluid delivery device in a closed-loop mode for automatically delivering fluid based on a difference between a first setpoint value and an analyte concentration value during operation of the fluid delivery device in the closed-loop mode. Additionally, the techniques may involve obtaining a second setpoint value. The second setpoint value may be a temporary setpoint value to be used for a period of time to regulate fluid delivery, and the second setpoint value may be greater than the first setpoint value. The techniques may further involve causing operation of the fluid delivery device for automatically reducing fluid delivery for the period of time based on the second setpoint value.